Aberrant expression of neuropilin-1 and-2 in human pancreatic cancer cells

被引:75
作者
Fukahi, K
Fukasawa, M
Neufeld, G
Itakura, J
Korc, M
机构
[1] Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Med, Irvine, CA USA
[2] Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Biol Chem, Irvine, CA USA
[3] Univ Calif Irvine, Div Endocrinol Diabet & Metab, Dept Pharmacol, Irvine, CA USA
[4] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[5] Yamanashi Med Univ, Dept Surg 1, Yamanashi, Japan
关键词
D O I
10.1158/1078-0432.CCR-0930-03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Neuropilin (Np)-1 and -2 are coreceptors for vascular endothelial growth factor (VEGF). This study was designed to assess their role in pancreatic ductal adenocarcinoma (PDAC). Experimental Design: We assessed Np-1 and Np-2 expression by real-time quantitative PCR in relation to the expression of VEGF ligands and receptors in pancreatic cancer cell lines and tissues. Results: ASPC-1, CAPAN-1, and PANC-1 pancreatic cancer cells and tumor-derived, laser-captured pancreatic cancer cells exhibited higher Np-1 and Np-2 mRNA levels than VEGF receptor-1, -2, or -3 mRNA levels. Transfection of Np-1 and Np-2 cDNAs in COS-7 cells, and treatment with tunicamycin revealed that both proteins were glycosylated. Both proteins were expressed in pancreatic cancer cell lines, in the PDAC samples, and in acinar cells adjacent to the cancer cells. The normal pancreas was devoid of Np-1 immunoreactivity, whereas Np-2 immunoreactivity was present in the endocrine islets and in some acinar cells, but not in ductal cells. Conclusions: The aberrant localization of Np-1 and Np-2 in the cancer cells in PDAC suggests that in addition to exerting proangiogenic effects, these coreceptors may contribute to novel autocrine-paracrine interactions in this malignancy.
引用
收藏
页码:581 / 590
页数:10
相关论文
共 49 条
[41]   Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis [J].
Takashima, S ;
Kitakaze, M ;
Asakura, M ;
Asanuma, H ;
Sanada, S ;
Tashiro, F ;
Niwa, H ;
Miyazaki, J ;
Hirota, S ;
Kitamura, Y ;
Kitsukawa, T ;
Fujisawa, H ;
Klagsbrun, M ;
Hori, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) :3657-3662
[42]   Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer [J].
Tang, RF ;
Itakura, J ;
Aikawa, T ;
Matsuda, K ;
Fujii, H ;
Korc, M ;
Matsumoto, Y .
PANCREAS, 2001, 22 (03) :285-292
[43]   A neuronal receptor, neuropilin-I, is essential for the initiation of the primary immune response [J].
Tordjman, R ;
Lepelletier, Y ;
Lemarchandel, V ;
Cambot, M ;
Gaulard, P ;
Hermine, O ;
Roméo, PH .
NATURE IMMUNOLOGY, 2002, 3 (05) :477-482
[44]   UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts [J].
Trompezinski, S ;
Pernet, I ;
Schmitt, D ;
Viac, J .
INFLAMMATION RESEARCH, 2001, 50 (08) :422-427
[45]   De novo expression of vascular endothelial growth factor in human pancreatic cancer:: Evidence for an autocrine mitogenic loop [J].
Von Marschall, Z ;
Cramer, T ;
Höcker, M ;
Burde, R ;
Plath, T ;
Schirner, M ;
Heidenreich, R ;
Breier, G ;
Riecken, EO ;
Wiedenmann, B ;
Rosewicz, S .
GASTROENTEROLOGY, 2000, 119 (05) :1358-+
[46]   Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF165 and VEGF121 [J].
Whitaker, GB ;
Limberg, BJ ;
Rosenbaum, JS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :25520-25531
[47]  
Wildi S, 1999, CLIN CANCER RES, V5, P2840
[48]   Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy [J].
Witte, L ;
Hicklin, DJ ;
Zhu, ZP ;
Pytowski, B ;
Kotanides, H ;
Rockwell, P ;
Böhlen, P .
CANCER AND METASTASIS REVIEWS, 1998, 17 (02) :155-161
[49]  
Yuan L, 2002, DEVELOPMENT, V129, P4797